| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Angela Dispenzieri | Q37838558 |
| Giampaolo Merlini | Q37839101 | ||
| Raymond L Comenzo | Q91638057 | ||
| P2860 | cites work | Amyloidosis: review of 236 cases | Q33146750 |
| Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | Q33151135 | ||
| Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial | Q33256792 | ||
| The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis | Q33372805 | ||
| Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report | Q33860770 | ||
| Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy | Q34208267 | ||
| Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. | Q34311781 | ||
| Primary systemic amyloidosis: clinical and laboratory features in 474 cases. | Q34320169 | ||
| Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice | Q34404023 | ||
| Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. | Q34437074 | ||
| Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone | Q34714894 | ||
| Molecular mechanisms of amyloidosis | Q35194628 | ||
| Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation | Q35849610 | ||
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis | Q35886289 | ||
| Dangerous small B-cell clones. | Q36516158 | ||
| Role of translational research advancing the understanding of the pathogenesis of light chain-mediated glomerulopathies | Q36857488 | ||
| Primary systemic amyloidosis--a diagnostic primer | Q38240985 | ||
| Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study | Q39127627 | ||
| Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation | Q39128093 | ||
| Beta 2-microglobulin predicts survival in primary systemic amyloidosis | Q41763171 | ||
| Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival | Q43675460 | ||
| Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | Q44388179 | ||
| Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis | Q44963523 | ||
| Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. | Q45016547 | ||
| The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). | Q45168852 | ||
| Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. | Q46909999 | ||
| High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study | Q47593423 | ||
| Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients | Q47801564 | ||
| Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis | Q48323509 | ||
| Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. | Q51954022 | ||
| Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. | Q52521552 | ||
| Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. | Q53671959 | ||
| Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis | Q55670644 | ||
| High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | Q57218202 | ||
| Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis | Q58030485 | ||
| Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis | Q58030559 | ||
| Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis | Q58853178 | ||
| Outcome of autologous stem cell transplantation for AL amyloidosis in the UK | Q58853185 | ||
| Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis | Q58853192 | ||
| Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate | Q60976770 | ||
| High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study | Q63413690 | ||
| The plasma cell labeling index: a valuable tool in primary systemic amyloidosis | Q69663660 | ||
| High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement | Q71100186 | ||
| Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis | Q72583329 | ||
| A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine | Q73247899 | ||
| Allogeneic bone marrow transplantation for AL amyloidosis | Q73954952 | ||
| Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients | Q74511292 | ||
| P433 | issue | Supplement 1 | |
| P304 | page(s) | 6-11 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego) | |
| P478 | volume | 14 |
| Q26823398 | Alternative donor transplant of benign primary hematologic disorders |
| Q46251291 | Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis |
| Q37172003 | Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis |
| Q33744195 | Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma |
| Q58609453 | Deferred autologous stem cell transplantation in systemic AL amyloidosis |
| Q46400142 | How to manage primary amyloidosis |
| Q37832199 | Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management |
| Q26827340 | Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment |
| Q34448455 | Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment |
| Q38928383 | Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment |
| Q37570615 | Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis |
| Q47643557 | Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation |
| Q35026460 | The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients |
Search more.